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Abstract : The patient with congenital hypogonadotropic hypogonadism (HH) shows low serum levels of andro-
gen, which is a group of sex hormones including testosterone, caused by the decreased gonadotropin release in 
the hypothalamus. Recent reports showed androgens exert protective effects against insulin resistance or ath-
erosclerotic diseases, such as diabetes mellitus or coronary artery disease. However, whether the juvenile hypo-
gonadism affects the diabetes or cardiovascular disease is unclear. We report a case of a middle-aged man with 
congenital HH who had severe coronary artery disease complicated with metabolic disorders. J. Med. Invest. 68 
: 189-191, February, 2021
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INTRODUCTION
 
Idiopathic congenital hypogonadotropic hypogonadism (HH) is 
a rare reproductive disorder that is caused by a gonadotropin-re-
leasing hormone (GnRH) deficiency (1). HH shows low plasma 
levels of luteinizing hormone (LH) and follicle-stimulating hor-
mone (FSH) accompanied with low or undetectable circulating 
androgen concentrations, which are male sex hormones includ-
ing testosterone. Congenital HH induces delayed puberty and 
infertility that is related to various metabolic disorders such as 
diabetes mellitus (DM), dyslipidemia or atherosclerotic disease 
(2, 3). Low testosterone concentrations in men are linked with 
insulin resistance, hyperglycemia, hypertension, dyslipidemia, 
and an increased risk of vascular disease (3). However, such 
cases in the real world are very rare. Here we presented a patient 
who had HH along with DM and coronary artery disease. 
CASE
A 48-year-old man with hypertension, dyslipidemia and DM 
was referred to our hospital due to dyspnea. He had untreated 
DM with diabetic neuropathy, proliferative diabetic retinopathy, 
and stage 3 diabetic nephropathy beginning at the age of 43 
years. His family history was negative for dyslipidemia ; how-
ever, his mother and younger brother—who died unexpectedly 
in his thirties—had DM. The patient’s height was 169.5 cm, 
body weight was 85 kg (indicated body mass index was 29.6), 
arm span was 175 cm, blood pressure was 100 / 64 mmHg, pulse 
rate was 92 beats per minute, body temperature was 37.3 ˚C, 
and saturation of percutaneous oxygen was 96% in room air. He 
had bipedal edema with bacterial infection and coarse crackles 
in both lower lungs. Furthermore, he manifested abnormal 
physical examination results such as anosmia, high-pitched 
voice, gynecomastia, impotence, and absence of pubic hair. His 
laboratory findings revealed severe inflammation (white blood 
cell count, 18300 [4000-9000] / μL ; C-reactive protein level, 
16.2 [ < 0.3] mg / dL). He demonstrated hyperglycemia (plasma 
glucose level, 306 [60-110] mg / dL ; hemoglobin A1c, 9.9 [4.6-
6.2] %). He additionally demonstrated dyslipidemia (level of 
low-density lipoprotein, 162 [70-140] mg / dL ; triglyceride level, 
141 [35-150] mg / dL ; high-density lipoprotein level, 61 [40-100] 
mg / dL), and he exhibited severe heart failure (brain natriuretic 
peptide, 1398 [< 18.4] pg / mL). Chest radiography revealed car-
diomegaly and pulmonary congestion. Additionally, a 12-lead 
electrocardiogram showed ST-level depression in V5 and V6, and 
transthoracic echocardiography revealed a low left ventricular 
ejection fraction of 20%. Computed tomography images revealed 
gynecomastia, a small penis, and cryptorchidism of the left 
testis (Figure 1). The estimated volume of each testis was ap-
proximately 1 ml. Coronary angiography exposed three-vessel 
disease, including total left anterior descending artery occlusion 
and severe stenosis of the left circumflex and right coronary ar-
teries (Figure 2). These findings indicated that the dyspnea was 
caused by ischemic heart failure.
We used insulin and sodium-glucose cotransporter 2 inhibi-
tors for diabetes and an angiotensin receptor blocker and loop 
diuretic for heart failure. The patient did not agree to undergo 
coronary artery bypass grafting ; hence, percutaneous coronary 
intervention was performed. Ischemic heart failure successfully 
improved after revascularization of the left anterior descending 
and right coronary arteries. The level of brain natriuretic pep-
tide improved from 1398 to 300 pg / mL, and his left ventricular 
ejection fraction, as measured by echocardiography, also im-
proved from 20% to 30%.
His physical examination showed no findings of secondary 
sex characteristics. Blood tests revealed very low serum levels 
of LH ( < 0.1 [0.6-12.1] mIU / mL), FSH (0.1 [0.9-12.0] mIU / mL), 
and testosterone (0.6 [2.6-8.7] ng / mL). Although the levels of 
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growth hormone and thyroid-stimulating hormone were slightly 
elevated, the other anterior pituitary hormones were normal. 
Contrast enhanced magnetic resonance imaging showed no ab-
normal pituitary grand or hypothalamic findings. The LH and 
FSH serum levels did not increase after the GnRH stimulation 
test (Figure 3). As these findings indicated HH, we had further 
diagnosed the patient to have congenital HH with early-onset 
DM and coronary artery disease. 
 
DISCUSSION
Although many reports showed that low testosterone level 
induces metabolic disorder, we report a patient who had HH, 
type 2 diabetes, and early-onset coronary artery disease. Idio-
pathic congenital HH is caused by the decreased gonadotropin 
release in the hypothalamus and is classified by some phenotype. 
Obesity may induce hypogonadism ; however, the patient’s body 
mass index was normal when he was young and his weight gain 
began at the age of 30 years. Some congenital HH cause men-
tal retardation, but his mental status was normal. Kallmann 
syndrome (KS) is one of the phenotypes of HH, which featured 
idiopathic GnRH deficiency and anosmia (1). The frequency of 
occurrence of KS is estimated to be approximately one in 8,000 
male individuals and it is featured in several disorders related 
to genes, including KAL1 and FEZF1 (1, 4). In this case, although 
anosmia with hypogonadism indicated the possibility of KS, the 
patient never consented to undergo urological, otolaryngological, 
and genetic examinations. Consequently, we could not obtain the 
diagnosis of KS and that is a limitation.
Recent reports showed testosterone deficiency induced met-
abolic disorder through hyperglycemia, insulin resistance, and 
progression of atherosclerosis regardless of age, body mass index 
or visceral fat (3, 5). In fact, the patient had arteriosclerosis 
obliterans of his bilateral below-knee arteries, typical of athero-
sclerotic disease. As for the vascular function, brachial-ankle 
pulse wave velocity showed higher-than-average levels given his 
age. A patient with type 2 diabetes or prediabetes reportedly had 
a high prevalence of low testosterone levels (6). Interestingly, 
testosterone replacement therapy prevented the progression of 
prediabetes to type 2 diabetes and improved glycemic control 
(7). Although evidences of testosterone therapy in men showed 
controversial results on cardiovascular disease prevention (8, 
9), many reports supported the protective effect of androgen 
against atherosclerosis (3, 7). In this case report, the patient did 
not undergo testosterone replacement therapy ; however, this 
treatment is an effective choice for patients with testosterone 
Figure 1.　Computed tomography (CT) image showing gynecomastia 
(yellow arrowhead) (A) and cryptorchidism (arrow) (B). Reconstructed 
CT image showing gynecomastia and a small penis (C).
Figure 2.　Coronary angiography shows three-vessel disease. (A) 
Total occlusion of the left anterior descending artery (arrow) ; (B) 
Total occlusion of the distal portion of the left circumflex artery (arrow) 
and severe stenosis of the middle portion of the left circumflex artery 
(arrowhead) ; (C) Severe stenosis of the proximal portion of the right 
coronary artery (arrowhead) and collateral arteries toward the left 
anterior descending artery (arrow).
Figure 3.　Serum luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) concentrations during the gonadotropin-releasing 
hormone (GnRH) stimulation test. Serum LH and FSH concentrations 
are very low at baseline and these hormones show no response to 
GnRH stimulation.
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deficiency.
Androgens have anti-atherosclerotic effects because the an-
drogen receptor (AR) is widely distributed in the cardiovascular 
system, including the endothelial and smooth muscle cells as 
well as fibroblasts. The AR predominantly mediates biological 
activities of androgens by the transcriptional control of target 
genes and interaction with multiple signaling pathways (10). 
AR activation decreases vascular remodeling through the phos-
phoinositide 3 / Akt / endothelial nitric oxide synthase activation 
and oxidative stress through the transforming growth fac-
tor beta / Smad pathway and improves angiotensin II-induced 
cardiac fibrosis (11, 12). As illustrated in Figure 4, androgen 
deficiency can induce various metabolic disorders that cause 
macroangiopathy (Figure 4). In this patient, both the activating 
renin-angiotensin-aldosterone system caused by heart failure or 
DM and low level of androgen would promote severe coronary 
atherosclerosis progression.
In male patients who have congenital HH, we should pay 
attention to metabolic disorders and atherosclerotic diseases, 
including early-onset coronary artery disease.
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Figure 4.　Prospective scheme of the main pathogenic pathway of 
testosterone deficiency. NO, nitric oxide ; PI3, phosphoinositide 3
